Diffuse Large B Cell Lymphoma Clinical Trials in Lexington, Kentucky

3 studies are recruiting for diffuse large b cell lymphoma in Lexington, Kentucky right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

    The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the treatment of rrDLBCL. This study will be divided into 2 parts: Dose Conf…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of Kentucky Chandler Medical Center ( Site 0158), Lexington, Kentucky
    Locations
    135 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT05139017 on ClinicalTrials.gov

  2. A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

    The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    University of Kentucky ( Site 0106), Lexington, Kentucky
    Locations
    275 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06717347 on ClinicalTrials.gov

  3. Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

    The study will measure the safety, tolerability, and efficacy with acalabrutinib in combination with rituximab in treatment-naïve elderly and/or frail patients with diffuse large B-cell lymphoma (DLBCL), who are otherwise unsuitable for standard front line chemoimmunotherapy treatments.

    Stage
    Phase 2
    Ages
    65 to 99
    Site
    Research Site, Lexington, Kentucky
    Locations
    57 in total
    Run by
    AstraZeneca

    See if you can join NCT05952024 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.